Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Increases Position in Vertex Pharmaceuticals Incorporated $VRTX

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA boosted its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 430.9% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,950 shares of the pharmaceutical company’s stock after purchasing an additional 3,206 shares during the quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in Vertex Pharmaceuticals were worth $1,669,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Norges Bank bought a new position in Vertex Pharmaceuticals during the 2nd quarter worth approximately $1,593,974,000. Jennison Associates LLC boosted its stake in Vertex Pharmaceuticals by 21.5% in the second quarter. Jennison Associates LLC now owns 6,151,505 shares of the pharmaceutical company’s stock valued at $2,738,650,000 after acquiring an additional 1,089,063 shares during the period. Assenagon Asset Management S.A. grew its holdings in shares of Vertex Pharmaceuticals by 214.6% during the third quarter. Assenagon Asset Management S.A. now owns 763,703 shares of the pharmaceutical company’s stock valued at $299,097,000 after purchasing an additional 520,949 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Vertex Pharmaceuticals by 2.1% during the 2nd quarter. Vanguard Group Inc. now owns 23,973,777 shares of the pharmaceutical company’s stock worth $10,673,126,000 after purchasing an additional 482,616 shares during the period. Finally, Alliancebernstein L.P. lifted its holdings in shares of Vertex Pharmaceuticals by 10.7% in the 2nd quarter. Alliancebernstein L.P. now owns 4,378,320 shares of the pharmaceutical company’s stock worth $1,949,228,000 after purchasing an additional 424,808 shares during the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on VRTX shares. Wells Fargo & Company lifted their price target on Vertex Pharmaceuticals from $460.00 to $515.00 and gave the company an “overweight” rating in a report on Wednesday, December 10th. Stifel Nicolaus cut their price objective on Vertex Pharmaceuticals from $455.00 to $445.00 and set a “hold” rating for the company in a report on Tuesday, November 4th. Citigroup lifted their target price on Vertex Pharmaceuticals from $550.00 to $575.00 and gave the stock a “buy” rating in a report on Thursday, October 2nd. Leerink Partners upped their price target on shares of Vertex Pharmaceuticals from $456.00 to $525.00 and gave the company an “outperform” rating in a report on Monday, December 29th. Finally, UBS Group assumed coverage on Vertex Pharmaceuticals in a research report on Tuesday, January 6th. They set a “buy” rating and a $535.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $503.80.

Insider Buying and Selling

In related news, EVP Charles F. Wagner, Jr. sold 9,532 shares of the stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an average price of $461.00, for a total transaction of $4,394,252.00. Following the sale, the executive vice president directly owned 37,725 shares in the company, valued at $17,391,225. This represents a 20.17% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Chairman Jeffrey M. Leiden sold 63,781 shares of the company’s stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $449.20, for a total value of $28,650,425.20. Following the transaction, the chairman directly owned 24,026 shares in the company, valued at approximately $10,792,479.20. This represents a 72.64% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 165,105 shares of company stock worth $73,858,523 in the last quarter. 0.20% of the stock is owned by corporate insiders.

Key Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Vertex reported progress advancing suzetrigine into a Phase‑3 trial for diabetic nerve pain — a meaningful new indication that could broaden revenue beyond its cystic fibrosis franchise. Vertex Advances Suzetrigine Phase 3 Trial
• Positive Sentiment: Wolfe Research upgraded the stock recently, and several sell‑side firms have raised price targets (e.g., Leerink, Wells Fargo), supporting upside expectations and a consensus target near ~$504. Vertex Stock Rating Upgraded by Wolfe Research
• Neutral Sentiment: Market recaps note short‑term price weakness even as fundamentals and analyst coverage remain constructive — context for volatile daily moves but not necessarily a change to the longer‑term thesis. Vertex Stock Dips While Market Gains: Key Facts
• Neutral Sentiment: Another market note highlighted the recent down‑day versus a broader market uptick — useful color for traders but not new company‑specific catalysts. Vertex Stock Falls Amid Market Uptick
• Negative Sentiment: Two senior executives disclosed sizable open‑market sales this week — EVP Charles Wagner Jr. sold 9,532 shares (~$4.4M at ~$461/share) and EVP Ourania Tatsis sold 4,500 shares (~$2.14M at ~$475/share). Large insider sales can pressure sentiment even if not tied to company fundamentals. Charles Wagner, Jr. Sells 9,532 Shares
• Negative Sentiment: Separate filing shows EVP Ourania Tatsis’ 4,500‑share sale and a near‑10% reduction in her position — another factor likely weighing on intraday selling pressure. Ourania Tatsis Insider Sale
• Negative Sentiment: A Seeking Alpha piece and some sell‑side notes discuss the near‑term cost and execution risk of expanding beyond cystic fibrosis, which can temper investor appetite until new indications (like suzetrigine) de‑risk. The Cost Of Growing Beyond Cystic Fibrosis (Rating Downgrade)

Vertex Pharmaceuticals Price Performance

VRTX stock opened at $463.86 on Monday. Vertex Pharmaceuticals Incorporated has a 52-week low of $362.50 and a 52-week high of $519.68. The stock has a market capitalization of $117.69 billion, a price-to-earnings ratio of 32.71 and a beta of 0.31. The company has a 50-day moving average of $443.50 and a two-hundred day moving average of $427.04.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Monday, November 3rd. The pharmaceutical company reported $4.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.58 by $0.22. Vertex Pharmaceuticals had a net margin of 31.35% and a return on equity of 23.51%. The business had revenue of $3.08 billion for the quarter, compared to the consensus estimate of $3.05 billion. During the same quarter last year, the company posted $4.38 earnings per share. Vertex Pharmaceuticals’s quarterly revenue was up 11.0% on a year-over-year basis. Equities analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.